LAPTM5 and neoplasm: As CD40 expression was frequently detected in glioblastoma tissue samples and is a prerequisite for the tumor-suppressive activity of LAPTM5, these data provide relevant molecular insights into a potentially new mechanism of resistance against temozolomide in a relevant proportion of glioblastoma patients.